NCT05636384 SupporTive Care At Home Research for Patients With Advanced Cancer (STAHR-cancer)
| NCT ID | NCT05636384 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Malignant Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 396 participants |
| Start Date | 2022-07-25 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 396 participants in total. It began in 2022-07-25 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To test the effects of home-based care on unplanned hospitalization within 6 months among advanced cancer patients with decreased performance status. Home-based care includes education for patients and their family caregivers, home visits by specialized home-based medical staff, and regular status check-ups.
Eligibility Criteria
Inclusion Criteria: Both the patient and their family caregiver must meet the criteria to be considered for this research. 1. Patient 1. A person who has an advanced-stage solid cancer diagnosis (ICD-10 code C00-C70); A person who is receiving or planning to receive cancer treatment 2. A person who meets one of the following conditions 1. Has been evaluated as having ECOG performance status 2 2. Has been evaluated as having ECOG performance status 1 and is over 70 years of age 3. A person who wishes to stay at home 4. A person whose family caregiver resides at home 5. A person who wishes to participate in the research 2. Family Caregiver 1. A family\* member of the patient \* Family: refers to the patient's spouse (including a common-law partner), descendants and their spouses up to the second degree, siblings and their spouses, and relatives and their spouses up to the eighth degree. 2. A person who meets one of the following conditions: 1. Lives with the patient (patient's household member) 2. Does not live with the patient, but visits the patient's home more than three times a week 3. A person who wants the patient to stay at home 4. A person who can communicate easily with medical staff 5. A person who wishes to participate in the research Exclusion Criteria: If either the patient or the family caregiver meets any one of these criteria, they are excluded from the study. 1. Patient 1. A person who cannot speak, hear, or read Korean 2. A person who is judged by a medical doctor to be unable to take part in this research due to extremely poor health 3. A person residing outside the range that can be visited by the respective medical institution (the conditions for distance are to be specified by each medical institution)\* \* This condition is not applicable for the control group. 4. A person who has used hospital- or home-type hospice and palliative care services 5. A person who is under the age of 19 2. Family Caregiver 1. A person who cannot speak, hear, or read Korean 2. A person who is judged by a medical doctor to be unable to take part in this research due to extremely poor health 3. A person under the age of 19
Contact & Investigator
Belong Cho, MD, MPH, PhD
PRINCIPAL INVESTIGATOR
Seoul National University Hospital
Frequently Asked Questions
Who can join the NCT05636384 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Malignant Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05636384 currently recruiting?
Yes, NCT05636384 is actively recruiting participants. Contact the research team at yoyo4284@snu.ac.kr for enrollment information.
Where is the NCT05636384 trial being conducted?
This trial is being conducted at Goyang-si, South Korea, Seongnam-si, South Korea, Seongnam-si, South Korea, Seoul, South Korea and 2 additional locations.
Who is sponsoring the NCT05636384 clinical trial?
NCT05636384 is sponsored by Seoul National University Hospital. The principal investigator is Belong Cho, MD, MPH, PhD at Seoul National University Hospital. The trial plans to enroll 396 participants.